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ABSTRACT
The human ,B-globin Locus Control Region (LCR) has
two important activities. First, the LCR opens a 200 kb
chromosomal domain containing the human E-, a- and
3-globin genes and, secondly, these sequences
function as a powerful enhancer of e-, ay- and ,B-globin
gene expression. Erythroid-specific, DNase I hyper-
sensitive sites (HS) mark sequences that are critical for
LCR activity. Previous experiments demonstrated that
a 1.9 kb fragment containing the 5' HS 2 site confers
position-independent expression in transgenic mice
and enhances human ,B-globin gene expression 100-
fold. Further analysis of this region demonstrates that
multiple sequences are required for maximal enhancer
activity; deletion of SP1, NF-E2, GATA-1 or USF binding
sites significantly decrease ,3-globin gene expression.
In contrast, no single site is required for position-
independent transgene expression; all mice with site-
specific mutations in 5' HS 2 express human ,B-globin
mRNA regardless of the site of transgene integration.
Apparently, multiple combinations of protein binding
sites in 5' HS 2 are sufficient to prevent chromosomal
position effects that inhibit transgene expression.
INTRODUCTION
Four erythroid-specific, DNase I hypersensitive sites are located
11 to 18 kilobases upstream of the E-globin gene in the human
,B-globin gene family (Fig. 1). These sequences are critical for
high-level expression of human E-, -y- and j-globin genes and,
therefore, have been designated the Locus Control Region (LCR)
(1-4). Deletions that remove these LCR sequences result in
severe f-thalassemias even in patients that retain an intact copy
of the f-globin gene (5-7).
Forrester et al. (8) have demonstrated that a deletion of 5' HS
2-4 in a Hispanic patient with ,B-thalassemia results in a dramatic
change of chromatin configuration and timing of DNA
replication. The j-globin locus on the mutant chromosome is
resistant to DNase I digestion in erythroid nuclei and is replicated
late in S phase of the cell cycle. The (-globin locus on the normal
chromosome of this heterozygous patient is sensitive to DNase
I digestion in erythroid nuclei and replicates early in S phase.
When the entire LCR is inserted upstream of globin genes and
tested for activity in transgenic mice, high-level expression is
observed specifically in erythroid cells (9, 10). Expression of
the linked globin genes is enhanced 300-fold and, all of the
animals that contain intact copies of the transgenes express
correctly initiated human globin mRNA.
These data strongly suggest that LCR sequences perform two
important functions. First, they 'open' a chromosomal domain
that encompasses the entire 3-globin locus specifically in erythroid
cells. This activity allows them to overcome integration-site,
position effects which normally inhibit expression of globin
transgenes in 30-70% of the animals. Secondly, they function
as a powerful enhancer that stimulates globin gene expression.
We previously demonstrated that a 1.9 kb KpnI-Pvull
fragment containing the 5' HS 2 site (Fig. 1) enhances human
j-globin gene expression 100-fold in transgenic mice and also
confers position independent expression (10, 11). Several other
groups have obtained similar data (12-16). To further define
important sequences within this region, 5' HS 2 ,B constructs
containing deletions of the 1.9 kb fragment were tested for LCR
activity in transgenic mice. The results of these experiments
demonstrate that multiple protein binding sites are important for
maximal enhancer activity. In contrast, no single site is required
for position-independent, transgene expression.
METHODS
Construction and analysis of 5' HS 2 a fragments
Plasmids were constructed by standard procedures (17). Fragment
preparation, microinjection, DNA and RNA analysis were as
described (18, 19). The limit of detection of ,B-globin mRNA
by the solution hybridization assay (18) is 1.0 pg; this value
corresponds to 3 molecules/cell assuming 20 pg ofRNA per fetal
liver cell and 20 jig of total RNA in the hybridization. Transgene
copy numbers for all animals that express human (-globin mRNA
are listed in Table 1; transgene copy numbers for non-expressors
were in the same range.
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Site-specific mutations in 5' HS 2 (K-P) ( were made in the
pSELECT system as described by the manufacturer (Promega).
The mutagenic oligonucleotides were as follows:
A8699-9653: 5' GGGTGTGTGC/ATCGATGTTCTCAGCC 3'
ASPI: 5' TCAGTGCCCCAC/TTCTGGTTCTGTGTA 3'
AH-8641: 5' CCAGCATCCTCATCTCTGAT/GGCTCAAGCACAGCAATGCT 3'
A8641-58: 5' CCTTCTAAGCAAACCTTCT/GCTGAGTCATGATGAGTC 3'
AAPIx2: 5' CAAGCACAGCAATGC/GCTGAGGCTTAGGGT 3'
8678-82S: 5' GCTGAGTCATGATGAGTCAttaatAGGCTTAGGGTGTGTGC 3'
NF-E5S: 5' GATGAGTCATGCTGctaacgAGGGTGTGTGCCCA 3'
8689-98S: 5' GAGTCATGCTGAGGCTTAGctagctagaCCAGATGTTCTCAGCCTAGAG 3'
AGATAl: 5' GCCTAGAGTGATGAC/GTCCCCAGCAGGATG 3'
AUSF: 5' AAGGAGAAGCTGACCAC/CTCCACCTCAAAC3'
AHSC: 5' AAGAAAATGGATGCC/GTGACATArTCTAGA 3'
The slashes (/) indicate the site of deletion and the small case
letters are mutated (scrambled) bases.
RESULTS
Analysis of 5' HS 2 (3-globin constructs in transgenic mice
Figure 1 illustrates the human (3-globin locus on chromosome
11 and an expanded view of the 1.9 kb KpnI-PvuII fragment
containing 5' HS 2. Previous experiments demonstrated that this
1.9 kb fragment confers position independent expression in
transgenic mice and strongly enhances human ,B-globin gene
expression specifically in erythroid cells. Figure 2A summarizes
our previous analysis of this fragment (11) and includes the
additional constructs described below. Each 5' HS 2 fragment
was inserted immediately upstream of a 4.1 kb human (-globin
gene. The constructs were purified from vector sequences and
injected into fertilized mouse eggs. These eggs were transferred
into the uteri of pseudopregnant foster mothers and embryos were
removed at 16 days of development. Total RNA was extracted
from fetal liver and analyzed for correctly initiated human and
mouse (-globin mRNA by primer extension (data not shown).
Human and mouse ,B-globin mRNA levels were quantitated by
solution hybridization (18). Table 1 lists the results of these
experiments and the data are summarized in Figure 2.
Figure 2A demonstrates that all 11 transgenic mice containing
intact copies of the 5' HS 2 (K-P) (3 construct express the
transgene, and the average level of human ,B-globin mRNA is
41.5% of endogenous mouse ,B-globin mRNA. When the human
(3-globin gene without LCR sequences is analyzed in mice only
7 of 23 transgenic animals express human (-globin mRNA and
the average level of expression is 0.3% of endogenous mouse
(-globin mRNA. Previous experiments also demonstrated that
enhancer activity is lost with deletions of both 5' and 3' sequences
of the 1.9 kb KpnI-PvuII fragment (11); however, all of the
transgenic animals that contained the 373 base pair HindIII-XbaI
fragment expressed correctly initiated human ,B-globin mRNA.
Constructs that did not contain the HindHI -XbaI fragment [5'
HS 2 (K-H) (, 5' HS 2 (X-Bg) , and (3] were not expressed
at high levels and only a fraction of these animals expressed the
transgene at all. These results suggested that multiple sequences
in the 1.9 kb fragment are involved in enhancer activity and that
sequences within the Hind]II-XbaI fragment are sufficient to
confer position independent expression. Analysis of additional
deletion constructs 5' HS 2 (K-Pp) ( and 5' HS 2 (K-8696) (
(Fig. 2) suggested that sequences which confer position
independent expression may lie between HindIII and position
8698 (marked by an asterisk). All of the transgenic mice
containing these constructs expressed correctly initiated human
,B-globin mRNA.
No single sequence necessary for position-independent,
transgene expression
To further define important sequences in this region a set of 7
constructs containing small deletions within the 217 bp
HindEJL-8698 fragment were analyzed in transgenic mice. Figure
2B indicates the specific sequences that are deleted or scrambled
in these constructs and also compares the human, mouse (20)
and goat (21, 22) 5' HS 2 sequences in this region. We anticipated
that mutations which do not inhibit enhancer activity but do affect
position-independent, transgene expression would result in high-
level expression in only a fraction of the animals. Surprisingly,
when all 7 constructs were tested, none of the deletions prevented
position-independent expression; all 87 transgenic mice expressed
the human (3-globin gene. These results suggest that no single
sequence in 5' HS 2 is necessary for position-independent,
transgene expression. Apparently, multiple combinations of sites
in 5' HS 2 are sufficient to prevent inhibitory, chromosomal
position effects regardless of the site of transgene integration.
This conclusion is supported by results from an additional deletion
construct, 5' HS 2 (AH-X) (,B which is listed at the bottom of
Fig. 2A. In this construct the entire HindEH-XbaI fragment was
deleted from 5' HS 2 (K-P) (3. Even in the absence of this
fragment, all transgenic mice expressed the human (3-globin gene.
In this case, protein binding sites in the KpnI-HindIII fragment
are juxtaposed to sites in the XbaI-PvulI fragment and,
presumably, form a novel complex that directs position-
independent, transgene expression.
Multiple sequences required for maximal enhancer activity
Although no single site is necessary for position-independence,
deletion of individual protein binding sites significantly affect
enhancer activity. We and others previously mapped protein
binding sites on the HinduI -XbaI fragment by DNase I
footprinting (11, 13-15, 23). Three prominent and three weaker
footprints were obtained. The SP1, NF-E2, NF-E5, GATA-1,
USF and HSC binding sites are indicated in Figure 2B. With
the exception of HSC, all of these sites were also detected by
in vivo footprinting (24, 25) [see Hardison et al. (26) for
summary]. As we demonstrated previously, deletion of the
duplicated NF-E2 sites in the HindIll -XbaI fragment reduces
expression of human (-globin mRNA to 2% of endogenous
mouse (-globin mRNA. The results in Figure 2A demonstrate
that deletion of the SP1, GATA-l and USF sites also significantly
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Figure 1. Human 3-globin locus. The human fl-globin locus on chromosome
11 is illustrated at the top of the figure. Black boxes represent individual globin
genes and arrows mark erythroid-specific, DNase I hypersensitive sites that flank
the locus. An expanded view of a 1.9 kb KpnI-PvuII fragment containing the
5' HS 2 sequence is illustrated below the locus. 5' HS 2 (K-P) ,B is a construct
that contains the 1.9 kb fragment inserted immediately upstream of a human 3-
globin gene.
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MOUSE CAGTGCTATCTGGGTCTCTAGGAGGAAGTCCACAGAAGGTG.... CCTAAAATCTCAACATTAC ACACCAGCATTACATGCA MGGGGACCCTGCCTTGCTGTGTGACATA..
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GOAT GACCTCTATCTGGGTCCCCAGCAGGAGGCTtACAGGACAGAT.. .TACAAAAA AAATACACTGCCTGACTGTA.AACCACCCAAGACAGCATCAGGGAGAAGAGGGATACTGAGGCAGAATGTGACGTAT.
Figure 2. Analysis of 5' HS 2 ($ constructs in transgenic mice. Panel A. Fragments containing deletions and point mutations in the 5' HS 2 region were inserted
upstream of a 4.1 kb fragment containing the human 3-globin gene. 5' HS 2 ,B fragments were purified from plasmid sequences and analyzed in transgenic mice
as described (10, 11, 18). Restriction sites are as follows: K, KpnI; S, Sacl; H, Hind]II; Pp, PpuMI; X, XbaI; B, BglII; P, Pvull. A refers to sequences or protein
binding sites that were deleted. Scramble (S) or xxx refers to sequences or protein binding sites that were replaced with random sequence. Quantitative values of
human 03-globin and mouse 3-globin mRNA were determined by solution hybridization with human ,B-globin and mouse 3-globin specific oligonucleotides as described
(10, 18). Data for some of the constructs have been published previously (10, 11) and are included for comparison. The results for AUSF include 2 fetuses that
were previously designated ANF-E (11). The results for 5' HS 2 (K-B) ,B and 5' HS 2 (K-X) ,B were inadvertently switched in Caterina et al. (11) and are listed
correctly here. Panel B. Sequence homology between the 5' HS 2 region of the human, mouse, and goat ,B-globin loci. Sites of protein/DNA interaction are marked
and the exact position of deletion and scramble mutants from Panel A are shown.
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decrease enhancer activity; all three deletions reduce j-globin
expression to approximately 10% per gene copy. Deletions of
the NF-E5 and HSC sites also reduce expression but to a lesser
extent (28% and 25%, respectively). These results and the results
of deletions upstream and downstream of the HindI -XbaI
fragment (Fig. 2A) demonstrate that the 5' HS 2 enhancer is
extremely complex and that multiple protein binding sites are
required for maximal enhancer activity.
The results described above differ from data recently published
by Ellis et al. (15).who demonstrated that deletion of GATA-1
and USF sites in a 215 bp synthetic 5' HS 2 did not inhibit
expression of a linked human 3-globin gene. In addition, Ellis
et al. (15) showed that mice containing only a single copy of
the transgene did not express human ,B-globin mRNA. In our
study all animals with single, intact copies of the transgene
expressed correctly initiated human j-globin mRNA and deletion
of GATA-1 and USF binding sites decreased expression of the
human 3-globin gene from approximately 40% per gene copy
to 10% per gene copy. The discrepancies in these data probably
result from the use of different 5' HS 2 fragments. Ellis et al.
(15) used a 215 bp synthetic 5' HS 2 fragment which has reduced
activity in transgenic mice. This 215 bp fragment is 4 fold less
active than the wild-type 375 bp HindIHl-XbaI fragment and the
HindIII-XbaI fragment is approximately S fold less active than
the 1.9 kb KpnI-PvuIH fragment used in our experiments. Our
GATA-1 and USF mutations were made in the context of the
entire 1.9 kb KpnI-PvuII fragment.
DISCUSSON
We previously suggested that the 5' HS 2 sequences required
for position-independent, transgene expression were located
within a 372 bp HindIII-XbaI fragment (11). This conclusion
was based on the observation that all constructs which contained
these sequences were expressed in transgenic mice regardless of
the site of transgene integration. To further define sequences
required for position independence, deletions throughout the
HindIllI-XbaI fragment were analyzed in transgenic mice.
Surprisingly, none of the mutations resulted in position-dependent
transgene expression; all transgenic mice that contained an intact
copy of the transgene expressed human 3-globin mRNA. We
subsequently deleted the entire HindI -XbaI sequence from the
1.9 kb KpnI-Pvull fragment and tested this construct in mice.
Again, all of the transgenic animals expressed correctly initiated,
human 3-globin mRNA. Apparently, juxtaposition of protein
binding sites in the KpnI -HindIII fragment and sites in the
XbaI -PvuII fragment form a novel complex that is capable of
directing position-independent transgene expression. At least 10
DNase I footprints are detected in the KpnI-HindIR fragment
and 3 footprints are detected in the XbaI -BglIl fragment
(Caterina and Townes, unpublished). These data suggest that
position-independence can be initiated by many different
combinations of sequences, and the results are consistent with
the observation that 5' HS 2, 3 and 4 each have LCR activity
(27) but share little sequence similarity.
Felsenfeld (28) recently suggested that a primary role of the
3-globin LCR is to inhibit nucleosome assembly on globin gene
promoters during DNA replication. According to this model,
LCR binding proteins form stable interactions with promoter
binding factors and keep the promotor in an open conformation
specifically in erythroid cells. Several groups have recently shown
Kadonaga (31) demonstrated that a Gal4/VP16 fusion protein acts
at a distance to prevent inhibition of target gene expression by
histone Hi-containing chromatin. Interestingly, the antirepression
activity of Gal4/VPI6 was characterized by a threshold effect
and multiple Gal4 binding sites were required for target gene
activation. Although multiple LCR binding proteins may act in
a similar manner, this model does not explain the change in
chromatin structure throughout the 200 kb globin locus. However,
a logical extension of this idea is that LCR binding proteins not
only inhibit nucleosome assembly (or at least histone
H1-containing chromatin assembly) at promoters but also at
several other critical points throughout the f-globin locus; lack
of nucleosome assembly at these sites may inhibit the formation
of higher order chromatin structures. Alternatively, LCR proteins
may prevent histone HI mediated repression indirectly by binding
small proteins such as HMG(I)Y which inhibit highly cooperative
HI -H1 interactions (34, 35). Several recent reports suggest that
HMG(I)Y and HMG(I)Y-like proteins have a wider role in gene
regulation than previously anticipated (36, 37). Regardless of the
mechanism involved, it is clear that multiple combinations of 5'
HS 2 binding proteins are capable of erythroid-specific, LCR
activity.
In summary, we have demonstrated that several protein binding
sites are involved in the enhancer activity of 5' HS 2. Deletion
of SP-1, GATA-1 and USF binding sites in the 1.9 kb
KpnI -Pvull fragment containing 5' HS 2 reduce human j-globin
gene expression from 41.5% per gene copy to approximately
10% per gene copy in transgenic mice. As demonstrated
previously, deletion of the duplicated NF-E2 sites reduces
expression to 2% per gene copy. Although these mutations inhibit
enhancer activity, none of them inhibit position-independent
transgene expression; all animals express the human 3-globin
gene regardless of the site of transgene integration. These results
demonstrate that no single protein binding site in 5' HS 2 is
necessary for position-independent, transgene expression.
Apparently, multiple combinations of protein binding sites in 5'
HS 2 are sufficient to prevent chromosomal position effects that
inhibit transgene expression.
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